Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
Humans
Female
Hyperprolactinemia
Cabergoline
/ therapeutic use
Prolactin
Hashimoto Disease
/ drug therapy
Thyroiditis, Autoimmune
/ drug therapy
C-Reactive Protein
/ analysis
Insulin Resistance
Glycated Hemoglobin
Uric Acid
Creatinine
Risk Factors
Cholesterol
Fibrinogen
/ analysis
Cardiovascular Diseases
/ prevention & control
Lipoproteins, HDL
cardiometabolic risk
dopamine agonists
insulin sensitivity
prolactin excess
thyroiditis
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
09
02
2023
accepted:
01
04
2023
medline:
11
7
2023
pubmed:
13
4
2023
entrez:
12
4
2023
Statut:
ppublish
Résumé
Both prolactin excess and autoimmune (Hashimoto) thyroiditis may predispose to the development of cardiometabolic disorders. The aim of this study was to investigate whether autoimmune thyroiditis determines cardiometabolic effects of cabergoline. The study population consisted of 2 groups of young women: 32 women with euthyroid Hashimoto thyroiditis (group A) and 32 individuals without thyroid disorders (group B). Both groups were matched for age, body mass index, blood pressure, and prolactin levels. Plasma prolactin, thyroid antibodies, glucose homeostasis markers, plasma lipids, circulating levels of uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen and homocysteine, and the urinary albumin-to-creatinine ratio were assessed before and after 6 months of cabergoline treatment. All women completed the study. Both groups differed in thyroid antibody titers, insulin sensitivity, high-density lipoprotein cholesterol, hsCRP, homocysteine, and the albumin-to-creatinine ratio. Although cabergoline treatment reduced prolactin levels, improved insulin sensitivity, decreased glycated hemoglobin, increased high-density lipoprotein cholesterol, decreased hsCRP, and reduced the albumin-to-creatinine ratio in both treatment groups, these effects (except for glycated hemoglobin) were more pronounced in group B than in group A. Only in group B, the drug decreased triglycerides, uric acid, fibrinogen, and homocysteine. In group A, hsCRP levels correlated with both baseline thyroid antibody titers and with other cardiometabolic risk factors. The impact of cabergoline on cardiometabolic risk factors depended on the degree of reduction in prolactin levels, while in group A additionally correlated with the effect of treatment on hsCRP. The obtained results suggest that coexisting autoimmune thyroiditis attenuates cardiometabolic effects of cabergoline in young women with hyperprolactinemia.
Substances chimiques
Cabergoline
LL60K9J05T
Prolactin
9002-62-4
C-Reactive Protein
9007-41-4
Glycated Hemoglobin
0
Uric Acid
268B43MJ25
Creatinine
AYI8EX34EU
Cholesterol
97C5T2UQ7J
Fibrinogen
9001-32-5
Lipoproteins, HDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
886-894Informations de copyright
© 2023, The American College of Clinical Pharmacology.
Références
Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia. J Clin Med. 2019;8:2203.
Vilar L, Vilar CF, Lyra R, Freitas MD. Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology. 2019;109:7-19.
Medic-Stojanoska M, Icin T, Pletikosic I, et al. Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia. Med Hypotheses. 2015;84:321-326.
Yavuz D, Deyneli O, Akpinar I, et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 2003;149:187-193.
Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest. 2003;26:341-346.
Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022;13:1015520.
Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab. 2018;13:99-106.
Kabootari M, Shirmohammadli H, Golgiri F, Mosalamiaghili S, Khajavi A, Akbari H. Metabolic effects of dopamine-agonists treatment among patients with prolactinomas. Endocrine. 2023;79:537-544. https://doi.org/10.1007/s12020-022-03238-x.
Negri M, Mannarino T, Giordano C, Gasperi M, Colao A, Pivonello R. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology. 2013;98:299-310.
Auriemma RS, Pirchio R, De Alcubierre D, Pivonello R, Colao A. Dopamine agonists: from the 1970s to today. Neuroendocrinology. 2019;109:34-41.
Krysiak R, Okopień B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin Pharmacol Toxicol. 2015;116:251-256.
Merrill SJ, Minucci SB. Thyroid autoimmunity: an interplay of factors. Vitam Horm. 2018;106:129-145.
Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13:391-397.
Mehran L, Amouzegar A, Azizi F. Thyroid disease and the metabolic syndrome. Curr Opin Endocrinol Diabetes Obes. 2019;26:256-265.
Krysiak R, Okopień B. The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto's thyroiditis. J Clin Endocrinol Metab. 2011;96:2206-2215.
Stamatelopoulos KS, Kyrkou K, Chrysochoou E, et al. Arterial stiffness but not intima-media thickness is increased in euthyroid patients with Hashimoto's thyroiditis: the effect of menopausal status. Thyroid. 2009;19:857-862.
Xiang GD, He YS, Zhao LS, Hou J, Yue L, Xiang HJ. Impairment of endothelium-dependent arterial dilation in Hashimoto's thyroiditis patients with euthyroidism. Clin Endocrinol. 2006;64:698-702.
Hu Y, Yao Z, Wang G. The relationship between the impairment of endothelial function and thyroid antibodies in Hashimoto's thyroiditis patients with euthyroidism. Horm Metab Res. 2020;52:642-646.
Ciccone MM, De Pergola G, Porcelli MT, et al. Increased carotid IMT in overweight and obese women affected by Hashimoto's thyroiditis: an adiposity and autoimmune linkage? BMC Cardiovasc Disord. 2010;10:22.
Krysiak R, Kowalcze K, Okopień B. Cardiometabolic risk factors in atorvastatin-treated women with euthyroid autoimmune thyroiditis. Pharmacology. 2023;1-10. https://doi.org/10.1159/000529242 [Online ahead of print].
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
Food and Drug Administration. Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Effect Reporting to IRBs - Improving Human Subject Protection. Washington; 2009.
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-1495.
Kamińska J, Dymicka-Piekarska V, Tomaszewska J, Matowicka-Karna J, Koper-Lenkiewicz OM. Diagnostic utility of protein to creatinine ratio (P/C ratio) in spot urine sample within routine clinical practice. Crit Rev Clin Lab Sci. 2020;57:345-364.
Borba VV, Zandman-Goddard G, Shoenfeld Y. Prolactin and autoimmunity. Front Immunol. 2018;9:73.
Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol. 2017;14:39-55.
Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab. 2011;96:273-288.
Farahmand M, Ramezani Tehrani F, Rostami Dovom M, Hashemi S, Azizi F. The impact of oral contraceptives on cardiometabolic parameters. J Endocrinol Invest. 2016;39:277-283.
Krysiak R, Gilowska M, Okopień B. The effect of oral contraception on cardiometabolic risk factors in women with elevated androgen levels. Pharmacol Rep. 2017;69:45-49.
Moutachakkir M, Lamrani Hanchi A, Baraou A, Boukhira A, Chellak S. Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein. Ann Biol Clin (Paris). 2017;75:225-229.
Mazziotti G, Sorvillo F, Naclerio C, et al. Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis. Eur J Endocrinol. 2003;148:383-388.
Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, Tang D, Chen R. Recent progress on the relationship between atherogenesis and inflammation. Biomolecules. 2018;8:80.
Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55:31-55.
Wei L, Zhang C, Chen HY, et al. Dopamine receptor DR2 expression in B cells is negatively correlated with disease activity in rheumatoid arthritis patients. Immunobiology. 2015;220:323-330.
Liontiris MI, Mazokopakis EE. A concise review of Hashimoto thyroiditis (HT) and the importance of iodine, selenium, vitamin D and gluten on the autoimmunity and dietary management of HT patients. Points that need more investigation. Hell J Nucl Med. 2017;20:51-56.
Nordio M, Basciani S. Treatment with myo-inositol and selenium ensures euthyroidism in patients with autoimmune thyroiditis. Int J Endocrinol. 2017;2017:2549491.
Auriemma RS, De Alcubierre D, Pirchio R, Pivonello R, Colao A. Glucose abnormalities associated to prolactin secreting pituitary adenomas. Front Endocrinol (Lausanne). 2019;10:327.
Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab. 2007;5:237-252.
Tavares G, Marques D, Barra C, et al. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes. Mol Metab. 2021;51:101241.
Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem. 1998;182:169-175.
Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148:241-251.
Mormile R. Induction of GLUT4 by inhibiting IFN-γ: a winning move to halt type 2 diabetes? Int J Colorectal Dis. 2016;31:1387.
DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34:789-794.
Dunn AJ. Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res. 2006;6:52-68.
Kars M, Pereira AM, Bax JJ, Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol. 2008;159:363-367.
Auriemma RS, Pivonello R, Ferreri L, Priscitelli P, Colao A. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am. 2015;44:89-97.
Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest. 2008;31:1119-1123.
George V, Johnson WD, Shahane A, Nick TG. Testing for treatment effect in the presence of regression toward the mean. Biometrics. 1997;53:49-59.